6 October 2020

In the new training network SkinTERM, 12 PhD candidates will search for a novel way of wound healing without scars and contractions. The European Union has granted more than 3 million euros to reach this goal. SkinTERM is coordinated by Radboudumc with Willeke Daamen as coordinator and Toin van Kuppevelt as vice coordinator (both RIMLS, theme Reconstructive and regenerative medicine, Dept. of Biochemistry). 

The SkinTERM consortium will address wound healing in a different way than the current standard autologous split-thickness skin (the epidermis with a tiny layer of dermis). Skin regeneration will be induced by key elements taken from the extracellular matrix of foetal and non-scarring species and by employing (stem) cells from relevant cellular origins. The starting point for the study is the remarkable capability of early foetal skin and skin from the spiny mouse (Acomys) to heal perfectly without scars/contraction and with appendices such as hair follicles. Novel biomaterials and skin substitutes will be developed and evaluated. In order to effectively embrace this new approach, the PhD candidates need to have knowledge in key elements of basic science, regenerative medicine and biomaterial sciences.

As translation to medical devices and especially advanced therapy medicinal products is currently too limited, we will give the PhD students a solid theoretical and practical foundation on topics like regulatory affairs, GMP and GCP, as well as secondments in industry. The SkinTERM program will thus create a new generation of entrepreneurial, multidisciplinary and inter-sectorially trained scientists with excellent career perspectives in either academia, industry or government.

The project starts from October 1 2020. All PhD students are expected to start in March 2021, where the Mobility Rule applies: Early Stage Researchers (ESRs/PhD-students) must not have resided or carried out their main activity (work, studies, etc.) in the country of the recruiting beneficiary for more than 12 months in the 3 years immediately before the recruitment date.

Recruiting companies:

  • Medskin Solutions Dr. Süwelack, Germany
  • CUTISS, Switzerland

Recruiting academic institutions:

  • Radboud university medical center, the Netherlands
  • University of Algarve, Portugal
  • VU medical center, the Netherlands
  • Helmholtz Zentrum München, Germany
  • Durham University, United Kingdom
  • University of Zurich, Switzerland

Partner organisations:

  • atoms & art, Belgium
  • OTR3, France
  • Paul Hartmann Group, Germany

read more

Related news items


Young Radboudumc researchers receive grant to engage in bio-medical and health research that is off the beaten path

16 September 2021

The ZonMw Off Road program is once again giving young scientists the opportunity to conduct innovative research in medical and/or health care. This research is off the beaten track and aims to bring about new insights and unexpected breakthroughs for healthcare and healthcare innovation.

read more

Infections increase risk to develop dementia

16 September 2021

In a recently published study, Radboudumc researchers investigated the effects of infectious events on cognitive decline and the development of dementia and its possible structural underpinning using pre- and post-infection MRI of the brain.

read more

Young Investigator Award for Alex Garanto

16 September 2021

Alex Garanto has been honored with the 2021 Mary Ann Liebert, Inc. publishers Young Investigator Award

read more

Depressive symptoms during pregnancy affect baby

16 September 2021

Study in Obstetrics & Gynecology shows associations between depression and adverse birth outcomes

read more

ENABLECARES launches a course on entrepreneurship for PhD candidates and postdocs

15 September 2021

Are you thinking about what to do after your PhD? Want to know more about entrepreneurship? This course gives you insight in many aspects of entrepreneurship and research in industry.

read more

Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias

15 September 2021

Lia Goltstein and colleagues published a study about effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis.

read more